老年弥漫大B细胞淋巴瘤联合化疗效果分析 |
|
|
【摘要】 目的 评价老年弥漫大B细胞淋巴瘤用美罗华联合化疗 治疗 的疗效及不良反应。 方法 观察12例老年(年龄大于65岁)弥漫大B细胞淋巴瘤用美罗华联合化疗治疗的情况,分别用R-CHOP方案治疗2-8疗程,之后用美罗华单药维持(每3个月一次,最长维持2年);分析美罗华联合化疗的疗效及不良反应。 结果 12例均达完全缓解(CR),无严重的不良反应。 结论 美罗华联合化疗治疗老年大B细胞性非霍奇金淋巴瘤可以提高疗效,并不增加毒副反应,可以改善DLBCL缓解的CR率及生存期,药物耐受好。 本文由中国论文联盟[2]Coiffier B,Lepage E,Briere J,et al.CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.N Engl J Med,2002,346(4):235-242. [3]Sehn LH,Jane DJ,Chhanabhai M,et al.Introduction of combined CHOP plus rituximab therapy improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol,2005,23:5027. [4]Pfreundschuch M,Truemper L,Gill D,et al.Fist analysis of the completed mabthera international (Mlnt)trial in young patients with low-risk diffuse large B-cell lymphoma(DLBCL):Addition of rituximab to a CHOP-like regimens significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI=0 and no bulky disease. Blood,2004,104:Abstract 157. [5]林桐榆.中山大学肿瘤防治中心,高危弥漫大B细胞淋巴瘤的诊断和治疗进展.肿瘤预防与治疗,2008(1): 1-7. [6]周立强. 中国 协和医科大学,肿瘤 医院 .临床肿瘤学进展,2006,3(2):907-910. [7]Demidem A,Lam T,Alas S,et al.Chimeric anti-CD20(IDEC-C2B8)monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytoxic drugs.Cancer Biother Radiopharm,1997,12(3):117-186. [8]Forer A,Lobuglio AF.History of antibody therapy for non-Hodgkin’s lymphoma.Semin Oncol,2003,30(6 Suppl 17):1-5. [9]Coiffer B,Hiaoun C,Ketterer N,et al. Rituximab (anti-CD20 monoclonal antibody)for the treatment of patients with relapsing or refractory aggressive lymphoma:multicenter phase Ⅱ study.Blood,1998,92(6):1927-1932. |
|
|
|
上一个论文: 中药不良反应的思考 下一个论文: 施工企业项目管理与成本控制 |
|